Lung adenocarcinoma
MONDO:0005061A carcinoma that arises from the lung and is characterized by the presence of malignant glandular epithelial cells. There is a male predilection with a male to female ratio of 2:1. Usually lung adenocarcinoma is asymptomatic and is identified through screening studies or as an incidental radiologic finding. If clinical symptoms are present they include shortness of breath, cough, hemoptysis, chest pain, and fever. Tobacco smoke is a known risk factor.
Also known as: adenocarcinoma of lung, adenocarcinoma of the lung, lung adenocarcinoma, non-small cell lung adenocarcinoma
2907 clinical trials for this condition and its sub-types, 114 tagged with Lung adenocarcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Lung adenocarcinoma
-
3 sub-types
-
Lung adenocarcinoma in situ 1 trial
-
Lung signet ring cell carcinoma 1 trial
-
Acinar lung adenocarcinoma 0 trials
-
Lung adenoid cystic carcinoma 0 trials
-
Lung colloid adenocarcinoma 0 trials
2 sub-types
-
Lung occult adenocarcinoma 0 trials
-
Papillary lung adenocarcinoma 0 trials
Most studied deeper sub-types
-
New drug targets Hard-to-Treat tumors in early trial
Disease control Stopped earlyThis study tested a drug called bemarituzumab in 260 adults with solid tumors that have high levels of a protein called FGFR2b. The main goals were to see if the drug is safe and if it can shrink tumors. Participants had already tried other treatments without success.
Phase 1/2 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Lung cancer drug combo study halted after just 4 patients
Disease control Stopped earlyThis study aimed to see if combining two drugs, bemcentinib and pacritinib, could help people with advanced lung adenocarcinoma that had stopped responding to other treatments. Only 4 patients were enrolled before the study was terminated early, so no conclusions can be drawn abo…
Phase 1/2 • Sponsor: The University of Texas Health Science Center at San Antonio • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Personalized lung cancer trial halted early, but shows promise
Disease control Stopped earlyThis study tested whether matching specific targeted drugs to the genetic changes in a person's ALK-positive lung cancer could improve treatment. It included 10 adults with advanced non-small cell lung cancer that had already been treated. The trial was stopped early due to low e…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Experimental cell therapy for advanced lung cancer shows early promise but trial halted
Disease control Stopped earlyThis early-stage trial tested a personalized treatment called GTE-001, which uses immune cells taken from a patient's own tumor to attack their cancer. It was designed for people with advanced lung adenocarcinoma that had stopped responding to standard chemotherapy. However, the …
Phase 1 • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Experimental immune cell therapy targets Hard-to-Treat cancers
Disease control Stopped earlyThis early-phase trial tested a personalized cell therapy called ITIL-306 in people with advanced ovarian, lung, or kidney cancers that had not responded to standard treatments. The therapy uses a patient's own immune cells (TILs) taken from their tumor, modified to better attack…
Phase 1 • Sponsor: Instil Bio • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Experimental lung cancer vaccine trial halted early
Disease control Stopped earlyThis early-stage trial tested an experimental immunotherapy called IMU-201 (PD1-Vaxx) in 24 adults with advanced non-small cell lung cancer. The treatment was given alone or combined with another immunotherapy drug (atezolizumab) and sometimes chemotherapy. The goal was to check …
Phase 1 • Sponsor: Imugene Limited • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Experimental combo for tough lung cancer hits dead end
Disease control Stopped earlyThis study tested two immunotherapy drugs, AK119 and AK112, with or without chemotherapy, in 59 people with a specific type of advanced lung cancer (EGFR-mutant non-squamous NSCLC) that had stopped responding to standard targeted pills. The goal was to see if the combination was …
Phase 1/2 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Cancer-Fighting super cells tested in solid tumors – study halted early
Disease control Stopped earlyThis study tested a personalized treatment where a patient's own immune cells were modified in a lab to recognize and attack unique markers on their cancer cells. It involved 8 people with advanced solid tumors like lung, pancreatic, or ovarian cancer that had not responded to st…
Phase 1/2 • Sponsor: Alaunos Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New drug targets genetic weakness in tough cancers
Disease control Stopped earlyThis phase 2 trial tested the drug tovorafenib (DAY101) in 23 people aged 12 and older with recurrent or progressive solid tumors that have specific genetic changes in the MAPK pathway. The goal was to see how many patients' tumors shrank or disappeared. The study was terminated …
Phase 2 • Sponsor: Day One Biopharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Lung cancer gene study halted early
Knowledge-focused Stopped earlyThis study looked at the genetics of people with multiple lung tumors (multifocal lung adenocarcinoma). Researchers collected tissue and blood samples from 100 participants during surgery to analyze their DNA. The goal was to see if genetic information could help guide treatment …
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC